Trial · NCT00535938
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cervical Dystonia | Baseline, SV1 (up to 505 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Blepharospasm | Baseline, SV1 (up to 542 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Hyperhidrosis | Baseline, SV1 (up to 1,273 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cerebral Palsy | Baseline, SV1 (up to 925 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Adult Focal Spasticity | Baseline, SV1 (up to 1,562 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Facial Nerve Disorder | Baseline, SV1 (up to 765 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| PRIMARY | Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Other Disorders | Baseline, SV1 (up to 568 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Scores on a Scale | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Cervical Dystonia | Baseline, SV1 (up to 505 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Blepharospasm | Baseline, SV1 (up to 542 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Hyperhidrosis | Baseline, SV1 (up to 1,273 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Adult Focal Spasticity | Baseline, SV1 (up to 1,562 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Cerebral Palsy | Baseline, SV1 (up to 925 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Facial Nerve Disorder | Baseline, SV1 (up to 765 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | BOTOX® Dose in Patients With Other Disorders | Baseline, SV1 (up to 568 days) | Efficacy Cohort: all enrolled patients who had a valid SF-6D score at baseline and at least one valid SF-6D score at a subsequent visit within the prospective period and who had data at this time point | Units | MEAN |
| SECONDARY | Concurrent Procedure Resource Utilization Patterns | Up to 1,785 days | Enrolled Cohort: All patients enrolled in the study | Patients | NUMBER |
| SECONDARY | Concurrent Surgical Procedure Resource Utilization Patterns | Up to 1,785 days | Enrolled Cohort: All patients enrolled in the study | Patients | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00535938/outcomes